Endo Health Solutions Inc (ENDP): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Endo Health Solutions ( ENDP) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 1.2%. By the end of trading, Endo Health Solutions rose $1.01 (3.8%) to $27.41 on heavy volume. Throughout the day, 2.9 million shares of Endo Health Solutions exchanged hands as compared to its average daily volume of 1.8 million shares. The stock ranged in a price between $26.70-$27.62 after having opened the day at $26.77 as compared to the previous trading day's close of $26.40. Other companies within the Health Care sector that increased today were: AcelRx Pharmaceuticals ( ACRX), up 22.8%, Electromed ( ELMD), up 14.5%, Synergy Pharmaceuticals ( SGYP), up 12.3%, and Palatin Technologies ( PTN), up 11.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo Health Solutions has a market cap of $3.02 billion and is part of the drugs industry. The company has a P/E ratio of 264.8, above the S&P 500 P/E ratio of 17.7. Shares are down 23.3% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Endo Health Solutions a buy, no analysts rate it a sell, and nine rate it a hold.

TheStreet Ratings rates Endo Health Solutions as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the negative front, Tranzyme ( TZYM), down 76.1%, CombiMatrix Corporation ( CBMX), down 35.1%, Natural Alternatives International ( NAII), down 22.9%, and AspenBio Pharma ( APPY), down 14.6%, were all laggards within the health care sector with Allergan ( AGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.